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Abstract
Aim We investigated the molecular mechanisms of hyperglycaemia-induced
insulin resistance and type 2 diabetes in rats receiving a continuous glucose
infusion (GI).
Methods Female Wistar rats were infused with either 2.8 mol/L glucose
or saline (2 mL/h) for durations varying from 0 to 15 days. Blood samples
were analysed daily to determine glucose and insulin dynamics. Subsets of
animals were sacrificed and solues muscles were extracted for determination
of protein expression, subcellular location, and activities of insulin-signalling
proteins.
Results Rats accommodated this systemic glucose oversupply and devel-
oped insulin resistance on day 5 (normoglycaemia/hyperinsulinaemia) and
type 2 diabetes on day 15 (hyperglycaemia/normoinsulinaemia). The effect
of GI on protein kinase Cζ (PKCζ ) activity was independent of changes
in phosphatidylinositol 3-kinase activity, and occurred in parallel with an
increase in PDK1 activity. Activated PKCζ was mainly located in the cytosol
after 5 days of GI that was coincident with the translocation of GLUT4 to the
plasma membrane, and normoglycaemia. After 15 days of GI, PKCζ translo-
cated from the cytosol to the plasma membrane with a concomitant decrease
in PDK1 activity. This caused an increase in the association between PKCζ and
PKB and a decrease in PDK1–PKB reactions at the plasma membrane, leading
to reduced PKB activity. The activity of PKCζ per se was also compromised.
The PKCζ and PKB activity reduction and the blunted insulin-stimulated
GLUT4 translocation eventually led to hyperglycaemia and diabetes.
Conclusion Translocation of PKCζ may play a central role in the
development of type 2 diabetes. Copyright  2009 John Wiley & Sons,
Ltd.
Keywords insulin resistance; type 2 diabetes; phosphatidylinositol-dependent
kinase 1; protein kinase B; protein kinase C ζ ; translocation
Introduction
Insulin resistance is a major pathogenic stage in the development of type 2
diabetes [1]. In humans and rodents, skeletal muscle is the most important tis-
sue for the maintenance of balanced postprandial glucose homeostasis: about
80% of insulin-stimulated glucose uptake is accounted for by muscle [2,3].
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Insulin increases glucose uptake in muscle by eliciting
translocation of the protein GLUT4 from an intracellular
storage site to both the plasma membrane (PM) and
the transverse (T)-tubules through a complex signalling
cascade [4,5]. Impaired GLUT4 translocation is linked to
reduced glucose utilization in skeletal muscle of insulin
resistant and type 2 diabetic humans [6,7]. Considerable
work has been done to elucidate the molecular
mechanisms regulating GLUT4 translocation. The general
consensus is that activation of phosphatidylinositol 3-
kinase (PI 3-kinase) via its interaction with insulin
receptor substrates (IRSs) [8] plays an essential role
[9,10]. In addition, downstream of PI 3-kinase, two
serine/threonine kinases, namely PKB/Akt and atypical
protein kinase C (PKC) ζ/λ have been implicated as major
transducer proteins of glucose transport in response to
insulin in different cell models [11,12]. However, it is
now clear that GLUT4 translocation can be activated
by different agents by a mechanism not involving the
proximal steps of the insulin-signalling cascade. For
example, bypassing the initial insulin signal transduction
steps, hyperosmolarity can stimulate GLUT4 translocation
and glucose transport through activation of a common
convergent signal transduction step downstream of
and/or in parallel to PI 3-Kinase/Akt [13,14].
Hyperglycaemia is a major factor contributing to
the development of peripheral insulin resistance in
patients with both type 1 and type 2 diabetes [15].
Restoration of glycaemia normalizes insulin action on
glucose transport in isolated skeletal muscle from type 2
diabetic subjects [16], and in animal models of diabetes
[17]. Thus, hyperglycaemia appears to have a profound
impact on insulin action through a desensitization of the
insulin-signalling transduction, but how it impairs insulin
action is largely unknown. Studies [18,19] show that
hyperglycaemia impairs insulin sensitivity and insulin-
stimulated phosphorylation/activation of Akt/PKB in
the liver of Zucker diabetic fatty rats. Also insulin-
induced Akt/PKB activation is reduced in skeletal
muscles incubated in medium containing glucose at high
concentration, without alteration of PI 3-kinase activity
[20]. Furthermore, insulin-induced Akt/PKB activation is
reported to be decreased in skeletal muscles of the diabetic
Goto-Kakizaki rat [17,21]. Thus, the reduced activation of
Akt/PKB is a candidate for the defects leading to insulin
resistance caused by hyperglycaemia in both the liver and
the skeletal muscle.
Interestingly, hyperglycaemia, just like hyperosmolar-
ity, in addition to its inhibiting effect on PKB and GLUT4
translocation, could stimulate glucose uptake directly.
Studies in diabetic patients revealed that hyperglycaemia
leads to increased glucose uptake in skeletal muscle in
a glucose concentration-dependent manner [22], but the
underlying mechanism is poorly understood. Studies on
cultured myotubes and isolated rat skeletal muscle tis-
sues have shown that short-term hyperglycaemia is an
insulin-independent inducer of GLUT4 translocation [23]
that involves PKC activation. Moreover, studies [23,24]
show that enhanced PKC activity is involved in mediating
insulin resistance. Taken together, these in vitro studies
indicate that acute increases in glucose activate PKC,
which on one hand induces insulin-independent glucose
uptake and, on the other hand, could mediate insulin
resistance.
The focus of the current study is on two members
of the AGC kinase super family: PKB/Akt and PKCζ .
PKCζ is the major atypical PKC in skeletal muscles
and adipose tissues of humans, monkeys, and rats.
It is considered as a negative regulator of PKB
[25] and is required for insulin-stimulated glucose
transport. To study the role of PKB and PKCζ in
the development of insulin resistance and diabetes
in vivo, we used the glucose-infused rat model originally
developed by Leahy et al. [26]. In this model, continuous
systemic glucose oversupply induces insulin resistance
(normoglycaemia/hyperinsulinaemia) and then overt
type 2 diabetes (hyperglycaemia/normoinsulinaemia).
This model mimics the pathobiochemical changes in
humans with nutrient oversupply and subsequent insulin
resistance associated with increased lipid accumulation
in adipose tissue and skeletal muscle. Using this model
we were able to observe in the hindlimb muscle dynamic
changes in insulin-signalling molecules such as PDK1,
PKCζ , PKB, and GLUT4 activities as well as their
localization in the development of insulin resistance and
type 2 diabetes.
Research design and methods
Materials
Reagents for sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and immunoblotting were obtained from
Biovision (Palo Alto, CA, USA) and the apparatus used
was from Bio-Rad (Richmond, CA, USA). Protein A/G-
Sepharose, Tris, NP-40, and nitrocellulosemembranes
were obtained from Sigma Chemical Co. (St Louis, MO,
USA). Monoclonal anti-Akt/PKB antibodies were pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). The anti-rat carboxy-terminal IRS-1 antibody
(Clone 8–63) was from NeoMarkers (Fremont, CA, USA).
Anti-PKCζ antibody and the antibody to the p85 Subunit
of PI-3-Kinase (αp85) was from Upstate Biotechnology
(Lake Placid, NY, USA). The monoclonal antibody to
PDK1 was from Transduction Laboratories (Lexington,
UK). The monoclonal anti-rat GLUT4 antibody was from
R&D Systems, Inc. (Minneapolis, AL, USA). Myristoy-
lated PKCζ pseudosubstrate peptide inhibitor was from
Biomol (Plymouth Meeting, PA, USA) and SH-6 from
Kamiya Biomedical Co. (Seattle, WA, USA). Enhanced
Chemiluminescence detection reagents were from KPL
(Gaithersburg, MA, USA). (γ -32P)ATP was from Amer-
sham (Aylesbury, UK). The Perfuser syringe pump was
purchased from Perfusor B. Braun (Melsungen, Germany).
All other chemicals used were of the highest analytical
grade.
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Animals
The Institutional Animal Experimentation Ethics Commit-
tee approved all surgical procedures performed in this
study, which followed established principles of laboratory
animal care (NIH publication no. 85-23, revised 1985).
Female Wistar rats weighing about 280 g were purchased
from the Experimental Animal Center of Wuhan Uni-
versity and were kept at 22 ◦C with a 12 : 12 h light-dark
cycle and a relative humidity of 55–60% during the whole
experimental period. The rats had free access to water and
standard chow pellet diet.
Prolonged glucose infusion into
conscious rats
Glucose infusion (GI) was performed as previously
described [27,28]. The age-matched rats undergoing
the infusion studies were anesthetized with Ketamine
(125 mg/100 g body weight, i.p.). Surgery was performed
under sterile conditions. A 1-cm long incision was made
between the sternum and the mandible; the right external
jugular vein was then exposed by blunt dissection and
dissected free of the surrounding connective tissue. The
jugular vein was ligated cranially and the vein was incised
distal to the ligature. A catheter filled with 50 IU heparin
in 0.9% saline was introduced into the vein so that its tip
laid just cranial to the right atrium. The catheter was then
anchored by double ligation. The free end of the catheter
was routed dorsally subcutaneous to the back of the neck.
A second incision was then made and the catheter was
externalized and fixed using an anchoring device. The
incision was then sutured. The externalized catheter was
routed through a flexible spring tether to a swivel and
connected by an oscillating arm to a Perfusor syringe
pump. The rats were housed singly in a metabolic cage
and allowed to recover for 48 h after which GI (2.8 mol/L
glucose) was started at a rate of 2 mL/h (group GR) versus
77 mmol/L saline infusion at 2 mL/h for controls (group
C). Glucose and saline infusions were carried out at the
same time. Blood samples were taken from the tail vein
and glucose and insulin concentrations were determined
as described [27].
Muscle isolation and preparation
After 5 or 15 days of continuous glucose or saline infusion,
experiments were terminated by disconnecting the syringe
pump. Rats were then immediately removed from the cage
and then anesthetized by pentobarbital (100 mg/kg i.p.).
The hind limb muscles were quickly excised before and
15 min after insulin injection (5 U/kg), dissected free of
connective tissue and fat and chopped into small pieces.
This step was carried out on ice. Chopped muscles were
immediately frozen in liquid nitrogen and subsequently
stored at −70 ◦C until further preparation.
2-deoxyglucose uptake assay
To investigate effects of PKB or PKCζ inhibition on
glucose transport in skeletal muscle of glucose-infused rats
after five days, we employed enzyme inhibition studies.
Hindlimb soleus skeletal muscles were removed, blotted
on gauze, and transferred to 25-mL flasks containing
2 mL of Krebs–Henseleit buffer (KHB) with 0.1% bovine
serum albumen, 32 mM mannitol, and 8 mM glucose. The
incubation studies of this muscle have been extensively
described [29]. The flasks were incubated in a shaking
water bath maintained at 30 ◦C for 1 h, and were
continuously gassed with 95% O2/5% CO2. Muscles
were initially incubated, respectively, in the presence
or absence of myristoylated PKCζ peptide inhibitor (PSζ )
(40 µM) or SH-6 (5 M), an inhibitor of Akt (PKB) for 1 h
prior to incubation under basal condition or stimulation
with insulin (13 nM) for 10 min. The muscles were
then transferred to flasks containing 2 mL of KHB with
0.1% bovine serum albumen, 40 mM mannitol, 2 mM
pyruvate, and the same additions as in the previous
incubation. The flasks were incubated for 10 min at 30 ◦C
to wash out glucose and the gas phase in the flasks was
maintained at 95% O2/5% CO2. Following the above
incubations, the muscles were rinsed by incubation in
KHB – 0.1% bovine serum albumen – 40 mM mannitol
with or without insulin for 10 min and blotted and
transferred to flasks containing 1.5 mL of KHB with
1 mM 2-deoxy-[1,2-3H] glucose (1.5 mCi/mmol), and
39 mM [1-14C] mannitol (8 µCi/mmol) and the same
additions as in the previous incubation. The flasks were
incubated at 30 ◦C for 20 min and continuously gassed
with 95%O2/5%CO2. Thereafter the muscles were frozen
and stored at −80 ◦C until processed for measurement of
2-deoxyglucose (2-DOG) transport. Frozen muscles were
dissolved and then processed, and the extracellular space
and intracellular 2-DOG concentrations were determined
as described previously [30]. Glucose transport activity is
expressed as µmol/20 min/mL intracellular water.
Skeletal muscle subcellular
fractionation
Cytosol and membrane fractions were separated as
described [31]. Briefly, frozen samples were homoge-
nized in a 10 : 1 volume to weight ratio of homoge-
nization buffer [20 mM Tris pH 7.5, 0.5 mM ethylene-
diaminetetraacetic acid (EDTA), 0.5 mM ethyleneglycol
bis(2-aminoethyl-ether)teraacetic acid (EGTA), 25 µg/mL
aprotinin, 25 µg/mL leupeptin, 10 mM NaF, 10% glyc-
erol, 5 mM MgCl2, 0.5 mM dithiothreitol] on ice using a
glass on glass homogenizer. The sample was centrifuged
for 20 min at 160 000 g in an ultracentrifuge. The super-
natant was collected as the cytosolic fraction. Half the
original volume of homogenization buffer was added to
the pellet, with 0.5% Triton X-100. The sample was fur-
ther homogenized on ice for 10–15 s and incubated on
ice for 30 min. The homogenate was then centrifuged
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at 160 000 g for 20 min. The resulting supernatant was
collected as the PM fraction.
PI 3-kinase activity
Muscle pieces were immediately homogenized in a
10× volume of ice-cold buffer A (in mM: 50 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
(pH 7.5), 137 NaCl, 1 MgCl2, 1 CaCl2, 10 Na4P2O7,
50 NaF, 2 EDTA, 40β-glycerophosphate, 2 Na3VO4, 0.2
phenylmethylsulfonyl fluoride (PMSF), and 1% NP-40,
10% glycerol, and 2 µg/mL aprotinin) and centrifuged
at 15 000 g at 4 ◦C for 30 min. Protein concentration
was determined using a commercial assay kit (Bio-Rad).
The supernatants containing equal amounts of protein
were immunoprecipitated overnight at 4 ◦C with anti-
IRS-1 antibody or anti-phosphotyrosine antibody coupled
to protein A Sepharose. The immunoprecipitates were
collected and washed. PI 3-kinase activities in the
immunoprecipitates were assayed as described [32].
PDK1 activity
A fragment of frozen muscle (25–30 mg) was homoge-
nized in 500 µL of ice-cold buffer containing 50 mM Tris
(pH 8.0), 0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA,
50 mM NaF, 5 mM Na4P2O7, 10 mM β-glycerophosphate,
1 mM sodium vanadate, µM microcystin, 20 mM
β-mercaptoethanol. Samples were solubilized by continu-
ous stirring for 40 min at 4 ◦C and centrifuged at 12 000 g
for 10 min at 4 ◦C. The supernatant was immunoprecip-
itated for 2 h at 4 ◦C with anti-PDK1 antibody coupled
to protein A/G Sepharose. The immune complex was
washed and PDK1 activity was determined as described
[33]. Radioactivity was counted using a Packard Tri-Card
2000 Ca liquid scintillation counter.
PKCζ activity
The remaining fragment of muscle (25–30 mg) was
homogenized in 600 µL of ice-cold buffer containing
20 mM of Tris/HCl (pH 7.5), 250 mM sucrose, 1.2 mM
EGTA, 20 mM β-mercaptoethanol, 1 mM PMSF, 5 µg/mL
leupeptin, 5 µg/mL aprotinin, 1 mM Na3VO4, 1 mM
Na4P2O7, 1 mM NaF, 1% Triton-X 100, 0.5% nonidet,
and 2 µg/mL pepstatin. Samples were solubilized by
continuous stirring for 30 min and centrifuged at
3000 g for 15 min at 4 ◦C. The supernatant was
immunoprecipitated with anti-PKCζ antibody coupled
to protein A/G Sepharose. The immune complex was
washed and suspended in Buffer B [50 mM Tris/HCl
(pH 7.5), 5 mM MgCl2, 100 µM Na3VO4, 100 µM
Na4P2O7, 1 mM NaF, and 100 µM phenylmethylsulfonyl
fluoride]. Suspensions were then incubated for 8 min
at 30 ◦C in 100 µL of Buffer B containing 3–5 µCi of
[γ -32P]ATP, 50 µM ATP, 4 µg of phosphatidylserine,
and 40 µM [159Ser]PKC-ε (AA153–164)-NH2 (Upstate
Biotechnology, Inc.), a preferred substrate for PKC-ζ .
Reactions were stopped by addition of 10 mL of 5% acetic
acid. PKCζ activity was determined as described [34].
Akt/PKB activity
PKB activity was measured as described by Kurowski
et al. [20]. Muscles were homogenized in a 10× volume
of ice-cold buffer C (in mM: 20 Tris pH 7.5, 250 sucrose,
10 NaF, 5 EDTA, 1 β-glycerophosphate, 2 Na3VO4, 0.2
PMSF, 0.2 NH4MbO4, 1 dithiothreitol, with 1% NP-40
and 2 µg/mL aprotinin) and centrifuged as for buffer A
(described above). The supernatants were immunopre-
cipitated overnight at 4 ◦C with anti-Akt/PKB antibody.
The immunoprecipitates were collected on protein A
Sepharose and washed. They were then incubated for
30 min at 25 ◦C in 40 µL of a reaction mix consisting
of kinase buffer to which had been added 100 µM (γ -
32P) ATP (10 µCi/Sample) and 30 µM crosstide (Upstate
Biotechnology). The reaction was stopped by spotting
5 µL of the mix on P81 phosphocellulose paper (What-
man) followed by 3 × 15 min washing with 1% H3PO4.
The papers were dried, and the radioactivity was deter-
mined by exposure to BAS 2000 film (Fuji-Film, Tokyo,
Japan). To investigate the inhibitory effects of PKCζ on
PKB activity in skeletal muscle PM of glucose-infused
rats after 5 or 15 days, PM fraction were incubated with




Thirty microgram aliquots from the cytosolic and
particulate fraction were used in the determination of
PKCζ expression and translocation. Aliquots (30–50 µg)
of homogenate prepared for the PI 3-kinase assay were
used for the determination of PI 3-kinase-p85, PDK1,
PKCζ and PKB concentrations. Proteins were subjected
to western blots using enhanced chemiluminescence -
Plus, as described previously [35]. The intensity (area
× density) of the individual bands on Western blots
was measured by densitometry (model GS-700, Imaging
Densitometer; Bio-Rad). The background was subtracted
from the calculated area.
PDK1–PKB reaction and PKCζ –PKB
association in the PM
Immunoprecipitation was used for the isolation of PDK1
and PKCζ . The protein concentrations of the membrane
fractions (separated as described above) were measured
and diluted with buffer to 10 µg protein/µL. Then 100 µL
of the latter dilution were added to 10 µL Protein A
Sepharose and 10 µL Sepharose and mixed. Anti-PDK1
or -PKCζ -antibodies (5 µg) were added and incubated
overnight at 4 ◦C. Beads were then centrifuged at
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500 rpm for 1 min. The pellet was washed three times
and resuspended in 20 µL washing buffer. Eventually,
Laemmli buffer was added and cups were heated at
98 ◦C for 10 min. Supernatants were then quantitatively
transferred to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (7.5 or 10% acrylamide), separated and
detected as described above. PDK1–PKB reactions and
PKCζ –PKB associations were determined using the anti-
Akt/PKB -antibody.
GLUT4 translocation in skeletal muscle
After 5 d or 15 d of GI, GLUT4 translocation in skeletal
muscle was measured using the method of Douen et al.
[36].
Statistical analysis
All data are expressed as means ± standard error of the
mean. Data were analysed using unpaired Student’s t
tests for the comparison of mean values. Data are also
expressed as percentages of control animals. p < 0.05 was
considered statistically significant.
The authors have full access to the data and take full
responsibility for the integrity of the data. All authors
have read and agree to the manuscript as written.
Results
Metabolic effects of continuous GI
Continuous GI for 10 days induced transient hypergly-
caemia and persistent hyperinsulinaemia (Figure 1A).
Hyperglycaemia peaked after 24 h of GI. Despite further
continuous GI, plasma glucose concentrations returned to
normal values on the fifth day compared with controls.
Plasma glucose concentrations in rats receiving continu-
ous GI was high relative to that in the control rats on the
tenth day, but the difference did not reach statistic signif-
icance. Serum insulin concentration increased ∼20-fold
after one day of GI, declined thereafter but remained sig-
nificantly elevated up to the tenth day as compared to the
control. Saline infusion affected neither plasma glucose
nor insulin concentrations in control rats (Figure 1A).
Serum insulin concentration recovered to normal and
the plasma glucose increased in glucose-infused rats by
the fifteenth day. Thus in this model the rats accom-
modated to systemic glucose oversupply and developed
insulin resistance before the tenth day and type 2 diabetes
by the fifteenth day. Because the metabolism of the rats
changed from normoglycaemic/hyperinsulinaemic on day
5 to hyperglycaemic/normoinsulinaemic on day 15, sub-
sequent studies were focused on these two time points.
Variations of body weight were presented in Figure 1B.
There was a general tendency for the animals to gain
weight with increasing length of infusion of either type,
this was significant on day 5 of infusion. The animals
gradually lost weight after day 5. The body weight in
glucose-infused rats significantly reduced by day 15 as
compared with day 0 of the same group or compared with
the saline-infused controls at day 15.
In vivo effects of GI on PI 3-kinase
expression and activity
Earlier studies with this model show that continuous
GI induces increased glucose metabolism and insulin
resistance in rat skeletal muscle [37–39]. Here, protein
levels of the downstream signalling proteins IRS-1,
PI 3-kinase-p85 was not affected, and no significant
Figure 1. Effect of glucose infusion on plasma glucose, insulin
concentrations and body weight. (A) The rats were treated
with glucose infusion with the indicated time as described
in Methods. Glucose and saline infusions were carried out
at the same time. Blood samples were taken from the tail
vein and glucose and insulin concentrations were determined
as described in Methods. Data representing results of six
independent experiments are expressed as means ± standard
error of the mean. ∗ p < 0.05; ∗∗ p < 0.01 glucose infusion verus
corresponding control rats. (B) Values are shown as means ±
standard error of the mean. ∗ p < 0.05 verus Day 0; p < 0.05
verus saline-infused animals. This figure is available in colour
online at www.interscience.wiley.com/journal/dmrr
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increases in basal IRS-1-associated PI 3-kinase activity
and total phosphotyrosine-dependent PI 3-kinase activity
were found in glucose-infused rats (Figure 2). Compared
with control rats, rats exhibited a reduced response to
insulin after either 5 or 15 days of GI. After insulin
stimulation the IRS-1-associated PI 3-kinase activity and
total phosphotyrosine-dependent PI 3-kinase activity of
glucose-infused rats after 5 days and especially after
15 days were reduced significantly compared with control
animals. Because activation of PI 3-kinase has been shown
to be an essential step in insulin-dependent stimulation
of glucose transport, these data show that the insulin
resistance in this model can be traced down to the
molecular level.
In vivo effects of GI on PDK1 protein
production and activity
GI for five days significantly increased basal PDK1
activity about twofold (Figure 2D, E), but did not affect
PDK1 protein expression. However, PDK1 activity was
significantly lower in glucose-infused rats on day 15 than
on day 5. Continuous saline infusion did not alter PDK1
activity or expression in control rats.
In vivo effects of GI on overall PKCζ
protein levels and activity
To delineate the mechanism by which continuous
changes in the extracellular glucose concentration might
contribute directly to insulin resistance and diabetes,
we determined PKCζ protein levels and activity in rat
skeletal muscle after 5 and 15 days of GI. GI did not
affect PKCζ protein levels (Figure 3A), but significantly
increased basal PKCζ activity about twofold (Figure 3B)
after 5 days. The PKCζ activity significantly decreased
and was lower than that in the control rats at day 15 of
continued GI. To elucidate which fraction is responsible
for the increased PKCζ activity at day 5 infusion, we
detected PKCζ activity in PM and cytosolic fraction. As
indicated in Figure 3C, five days of GI resulted in dramatic
increase of PKCζ activity in the cytosolic instead of PM
Figure 2. Total p85, phosphatidylinositol 3-kinase (PI 3-kinase) activity associated with insulin receptor substrate (IRS)-1 and
total PI 3-kinase activity, PDK1 protein and activity in the skeletal muscle of control and glucose-infused rats. Homogenates were
prepared from glucose-infused (GI) and control (C) rats and western blotting was performed to detect the p85 and PDK1. Protein,
immunoprecipitated with anti-IRS-1 or anti-phosphotyrosine antibody, was subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis followed by immunoblotting with anti-p85 antibody and determination of IRS-1-dependent PI 3-kinase activity and
total PI 3-kinase activity. The other protein was immunoprecipitated with anti-PDK-1 antibody and subjected to determination of
PDK1 activity as described in the Materials and Methods. (A) Representative immunoblot analysis showing p85 content (top) and
quantification (bottom) of p85 protein levels by scanning densitometry. (B) PI 3-kinase activity associated with IRS-1. (C) Total PI
3-kinase activity. Data shown are means ± standard error of the means of four independent experiments. Values are expressed
as percentages of controls. ∗ P < 0.05 basal verus insulin-stimulated conditions; , p < 0.05 verus corresponding control rats.
(D) Representative immunoblot analysis showing the presence of PDK1 (top) and quantification (bottom) of PDK1 protein levels by
scanning densitometry. (E) PDK1 activity. Data shown are means ± standard error of the means of four independent experiments.
Values are expressed as percentages of controls. ∗ p < 0.05; ∗∗ p < 0.01 verus controls, , p < 0.05 verus GI on day 5
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fraction, suggesting that PKCζ is primarily activated in
the cytosol after glucose challenge.
Effects of PSζ or SH-6 on 2-DOG uptake
in skeletal muscle of glucose-infused
rats after 5 days
As shown in Figure 3D, the basal 2-DOG uptake
dramatically elevated (approximately threefold) and
maximally insulin-stimulated rates of 2-DOG uptake was
impaired in 5 days of glucose-infused rats compared
with saline-infused rats. To gain more insight into the
mechanism of glucose transport in insulin-resistant state,
we measured 2-DOG uptake in skeletal muscle pretreated
with myristoylated PKCζ peptide inhibitor (PSζ ) or SH-6,
a specific inhibitor of Akt/PKB in 5 days of glucose-
infused rats. 2-DOG uptake in skeletal muscle was
reduced by 78% and 66% (p < 0.05), respectively, in PSζ -
treated basal and insulin-stimulated groups compared
with their corresponding non-treated groups. However,
2-DOG uptake was reduced by 19% and 18% (p < 0.05),
respectively, in SH-6-treated basal and insulin-stimulated
groups compared with their corresponding non-treated
groups. Combination of PSζ and SH-6 treatment caused a
dramatic reduction of 2-DOG uptake, to a level of 10% of
the values in non-treated groups both in basal and insulin-
stimulated muscle (Figure 3D). These data suggest that
PKCζ may be mainly responsible for glucose transport in
skeletal muscle in insulin-resistant state. In addition, as
indicated in Figure 3D, 2-DOG uptake was dramatically
impaired at day 15 of GI relative to day 5.
The translocation of PKCζ
High glucose is known to activate PKC isoforms,
which inhibit insulin signalling and stimulate GLUT4
translocation. Therefore, the cellular localization of the
PKCζ isoform was studied to assess possible activation
under these experimental metabolic conditions. An
increase in PKCζ protein content was seen in the cytosolic
fractions after five days of GI, although it did not reach
statistical significance (Figure 4). However, the activated
Figure 3. The active PKCζ , which is mainly located in cytosol after glucose challenge, is responsible for glucose transport in
skeletal muscle in insulin-resistant state. Homogenates were prepared from glucose infused (GI) and control (C) rats and western
blotting was performed to detect the PKCζ protein. Protein was immunoprecipitated with anti-PKCζ antibody coupled to protein
A/G Sepharose and subjected to determination of PKCζ activity as described in the Materials and Methods. (A) Representative
immunoblot analysis showing PKCζ presence (top) and quantification (bottom) of PKCζ protein levels by scanning densitometry.
(B) PKCζ activity. Data shown are means ± standard error of the means of four independent experiments. Values are expressed
as percentages of controls. ∗ p < 0.05; ∗∗ p < 0.01 verus corresponding controls, , p < 0.05 verus GI on day 5. (C) PKCζ activity
in plasma membrane and cytosolic fraction. n = 3; ∗ p < 0.05 verus control group. (D) Effects of PSζ or SH-6 on 2-DOG uptake in
skeletal muscle of glucose-infused rats. The soleus muscles were removed and incubated in the presence or absence of myristoylated
PKCζ peptide inhibitor (PSζ ) (40 µM) or SH-6 (5 M), an inhibitor of Akt (PKB) for 1 h prior to incubation under basal conditions
or stimulation with insulin (13 nM). 2-deoxyglucose uptake was measured as described in ‘Materials and Methods.’ Values are the
means ± standard error of the means of four independent experiments. ∗, p < 0.05 basal verus insulin-stimulated conditions; ,
p < 0.05 verus non-treated groups on day 5; †, p < 0.05 verus corresponding non-GI groups
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Figure 4. Effect of glucose infusion on the translocation of PKCζ in rat skeletal muscle. Hind limb skeletal muscles were prepared
from glucose-infused or saline-infused (C) rats and the plasma membrane and cytosol fractions were obtained as described in
the Materials and Methods. Representative western blots indicating PKCζ contents in plasma membrane (A) and cytosol fractions
(B) are shown from a set of four independent experiments. The upper panels: Quantification of PKCζ protein levels in plasma
membranes and cytosol fractions by scanning densitometry. Data are shown as means ± standard error of the means. Values are
expressed as percentages of corresponding control values. ∗ p < 0.05 verus corresponding control rats
PKCζ by GI is mainly located in the cytosol after five
days of GI. Thereafter, PKCζ was enriched in the PM after
15 days of GI and the corresponding cytosolic fractions
were depleted (Figure 4). Quantitatively, GI caused more
than fourfold enrichment of PKCζ in the PM. Thus,
continuous GI led to translocation of PKCζ from the
cytosol to the PM.
In vivo effects of GI on Akt/PKB content
and activity
The protein levels of Akt/PKB did not differ between
the groups (Figure 5A). No significant increase in basal
PKB activity was found in glucose-infused rats after
five days, whereas it was reduced to about 44% of
controls after 15 days (Figure 5B). In control rats, insulin
administration resulted in a noticeable increase in PKB
activity (Figure 5B). GI after 5 days and 15 days resulted
in reduced response to insulin, and the activity of Akt/PKB
after insulin stimulation was decreased by 22% and 56%
(p < 0.05), respectively, compared with values measured
in control rats.
In vivo effects of GI on PDK1–PKB
reaction and PKCζ –PKB association
at PM
Binding studies have shown that PKB associates in vitro
with the α, δ, and ζ isoforms of PKC [40]. We performed
Figure 5. In vivo effects of GI on Akt/PKB protein content and activity in skeletal muscle of Wistar rats. The total lysate was
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting with anti-Akt/PKB antibody
(A). An equal amount of muscle protein was immunoprecipitated with anti-Akt/PKB followed by determination of Akt/PKB activity
(B). (A) representative immunoblot analysis showing Akt/PKB presence (bottom) and quantification (top) of Akt/PKB protein levels
by scanning densitometry. (B) Akt/PKB activity in skeletal muscle. Data are shown as means ± standard error of the means of three
independent experiments. Values are expressed as percentages of controls. ∗, p < 0.05 basal verus insulin-stimulated conditions;
, p < 0.05 verus corresponding control rats
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co-immunoprecipitation studies using PM fractions of
skeletal muscle to investigate the possible interactions of
PKCζ as well as PDK1 with PKB in vivo. Endogenous PDK1
and PKCζ were immunoprecipitated from membrane
fractions. PKB was detected in the PKCζ and PDK1
immunoprecipitates using western blotting (Figure 6A,
B). The amounts of PDK1–PKB reactions and PKCζ –PKB
associations at PM were not different between the control
rats and glucose-infused rats after five days of GI.
Interestingly, GI for 15 days led to a significant threefold
increase in PKCζ –PKB association at the PM, whereas at
the same time, the PDK1–PKB reaction was reduced to
approximate 40% of the controls (Figure 6A, B). These
results clearly demonstrate that the association between
PKCζ and PKB is negatively correlated with PDK1–PKB
reactions at the PM. We propose that this demonstrates
competitive inhibition.
Effects of PSζ on PKB activity in
skeletal muscle PM of glucose-infused
rats
To confirm whether or not PKCζ inhibited PKB activity
after its membrane translocation, PM fraction of glucose-
infused rats after 5 or 15 days were isolated and
incubated with 25 µM PSζ for an hour and PKB activity
was measured. The specific PKCζ inhibitor, PSζ , was
used to selectively inhibit PKCζ activity. PKB activity
in cytosol fraction could not be detected. PSζ did not
alter PKB activity in PM of saline-infused rats (data
not shown). Basal and insulin-induced PKB activity in
PM was significantly lower in glucose-infused rats on
day 15 than on day 5. As expected, basal and insulin-
induced PKB activity in PM was considerably increased
after PSζ treatment in glucose-infused rats on day 15
when compared with non-treated groups (Figure 6C). It
is logical to speculate that the inhibition of PKB activity
might, at least partly, attribute to PKCζ in PM. Taken
together, these data show for the first time in skeletal
muscle that PKCζ can inhibit PKB after translocation
to PM.
In vivo effects of GI on GLUT4
translocation in skeletal muscle
GLUT4 protein levels were similar between control and
glucose-infused rats (data not shown). GI for 5 days
significantly increased GLUT4 protein levels in the PM
but decreased the amount of GLUT4 protein in the low-
density microsome fractions (Figure 7A, B), suggesting
that glucose oversupply alone could contribute to increase
in basal GLUT4 translocation at day 5. The insulin-
stimulated translocation of GLUT4 from the low-density
microsome to the PM fractions in skeletal muscle was
blunted progressively from 5 days to 15 days of GI
(Figure 7A, B).
Discussion
Hyperglycaemia impaires insulin signalling, but the
underlying mechanism is not fully understood [41]. To
address the molecular mechanisms underlying glucose-
induced insulin resistance and diabetes, we employed
the glucose-infused rat model. Inadequate pancreatic
β-cell function is an essential component of all forms
of diabetes. In our animal model, rats accommodating
systemic glucose oversupply developed insulin resistance
after 5 and 15 days, which can be traced down to
the molecular level. Compared with control rats, rats
exhibited a reduced response to insulin after either
5 or 15 days of GI. The insulin-stimulated IRS-1-
associated PI 3-kinase activity and total phosphotyrosine-
dependent PI 3-kinase activity (Figure 2B, C), insulin-
stimulated DOG-uptake (Figure 3D), insulin-stimulated
PKB activity (Figure 5B) and insulin-stimulated GLUT4
PM-expression (Figure 7B) were reduced significantly
compared with control animals, clearly indicating insulin
resistance at the level of muscle. To maintain glucose
homeostasis, β-cells increase insulin secretion and release,
and the resulting enhanced insulin concentrations can
compensate for insulin resistance. With the development
of insulin resistance, β-cell exhaustion occurs by depletion
of the readily releasable pool of intracellular insulin
following prolonged exposure to a secretagogue [42].
After prolonged exposure to elevated glucose, pancreatic
β-cell function is progressively and irreversibly impaired
by chronic hyperglycaemia and over secretion. This
detrimental effect is referred to as ‘glucotoxicity’ [43].
At this point, β-cells decompensate and reduce insulin
secretion, so hyperglycaemia and overt diabetes emerge,
which was shown in our animal model after 15 days
of GI (hyperglycaemia/normoinsulinaemia). In addition
to inducing functional changes, chronic hyperglycaemia
can also decrease β-cell mass by inducing apoptosis
[44].
A novel mechanistic finding of the current study is
that the normalization of blood glucose concentration in
insulin resistance state was mediated at least partially by
an increased translocation of the GLUT4 protein to the
PM of skeletal muscle. The insulin-signalling transduction
on day 5, as assessed by the determination of protein
amounts and basal activities of PI 3-kinase and PKB, was
not further increased when compared to control rats. PI
3-kinase activity and PKB/Akt activity after stimulation
with exogenous insulin were impaired in skeletal muscle
of glucose-infused rats after five days. Furthermore, the
effect of glucose on PKCζ was independent of changes
in PI 3-kinase activity, and occurred in parallel with an
increase in PDK1 activity. Our findings are consistent
with an earlier report of Steiler et al. that basal PKCζ
activity was increased under hyperglycaemic conditions
in Goto-Kakizaki and Wistar rats [45]. This finding
of increased PKCζ activity was confirmed in vitro in
isolated soleus muscle exposed to high extracellular
glucose, and occurred concomitant with an increase in
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Figure 6. The translocation of PKCζ to plasma membrane after 15 days of GI increases PKCζ -PKB association and inhibits PKB
activity. The membrane fractions of skeletal muscle were prepared and incubated with antibodies against PDK1 or PKCζ as described
in the Materials and Methods. Immunoprecipitates were analysed for the presence of PKB by western blotting using anti-Akt/PKB
monoclonal antibody. (A) Representative immunoblot analysis showing PKCζ –PKB association (top) and quantification (bottom)
of PKCζ –PKB associated protein levels by scanning densitometry. (B) Representative immunoblot analysis indicating PDK1–PKB
reactions (top) and quantification (bottom) of PDK1–PKB associated protein levels by scanning densitometry. Data shown are
means ± standard error of the means of three independent experiments. Values are expressed as percentages of controls. ∗∗ p < 0.01
verus corresponding control rats. C, Effects of PSζ on PKB activity in skeletal muscle plasma membrane of glucose-infused rats.
Plasma membrane fraction of glucose-infused rats after five or 15 days were isolated and incubated with 25 µM PSζ for an hour and
PKB activity was measured as described in ‘Materials and Methods.’ Data shown are means ± standard error of the means of four
independent experiments. Values are expressed as percentages of insulin-stimulated groups of non-PSζ -treated plasma membrane
of glucose-infused rats after 5 days. ∗, p < 0.05 basal verus insulin-stimulated conditions; , p < 0.05 verus non-PSζ -treated groups
of glucose-infused rats after 15 days
PDK1 activity. Their study also authenticated that acute
hyperglycaemia leads to a parallel increase in PDK-1
and PKCζ phosphorylation/activity via a PI 3-kinase-
PKB/Akt-independent mechanism. Taken together, these
data suggest that the concentration of glycaemia may
directly regulate PKCζ activity in skeletal muscle. In the
present study, when PKCζ was inhibited using a specific
inhibitor, PSζ , basal and insulin-induced 2-DOG uptake
in skeletal muscle of glucose-infused rats after 5 days
were reduced by 78% and 66%, respectively. Thus, it
is mainly PKCζ rather than PKB that leads to increases
in translocation of GLUT4 to the PM of skeletal muscle,
which maintains normoglycaemia in the insulin-resistant
state.
PDK1 is a downstream target of PI 3-kinase that was first
described as an activator of PKB/Akt [46] and was later
shown to activate members of the AGC kinase superfamily
including PKCζ [47]. However, glucose increases activity
of PKCζ rather than PKB/Akt indicating the existence of
a divergence in the effects of PDK1 on these downstream
substrates in the insulin-resistant state. The intracellular
location of the temporary complex formed by PDK1 and its
substrates can determine substrate specificity. Studies in
3T3 L1 adipocytes, in which wild type or PM-targeted
PDK1 are overexpressed, show that full activation of
PKB/Akt requires PDK1 translocation to the PM, whereas,
PKCζ can be fully activated independently of insulin by
overproduction of wild-type cytosolic PDK1 [48]. Thus,
differences in the intracellular compartmentalization of
PDK1 may provide a mechanism for these divergent effects
on PKB/Akt and PKCζ .
PKCζ was originally discovered as a unique PKC isotype
[49]. To date in mammals, it is classified into the atypical
PKC subfamily, based on its structural similarity to PKC
λ/ι. Here we have shown that activation of PDK1 and
PKCζ can be regulated by changes in the extracellular
glucose concentration. Intriguingly, the activated form
of PKCζ is found in the cytosol after five days of GI.
These results provide proof of concept for the first time
that when activated, PKCζ mainly retains in the cytosol
rather than immediately translocates. Given that 5 day of
GI increases PKCζ activity and glucose uptake, which
is coincident with an increased GLUT4 translocation,
we speculate that the activated PKCζ contributes to
the translocation of GLUT4 to PM and maintenance of
normoglycaemia. Taken together, this striking activation
of PKCζ in the cytosol seems to serve as a compensatory
mechanism for maintaining glucose homeostasis in the
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Figure 7. Effects of glucose-infusion on GLUT4 translocation in skeletal muscle tissues from Wistar rats. The plasma membrane and
low-density microsome fractions isolated from skeletal muscles of saline-infused (C) or glucose-infused (GI) rats were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting with anti-GLUT4 antibody. Representative
immunoblot analyses showing GLUT4 protein levels (top) and quantified data (bottom) of GLUT4 protein in low-density microsome
(A) and plasma membrane (B) fractions. Results are expressed as means ± standard error of the means of three independent
experiments. Values are expressed as percentages of controls. ∗ p < 0.01 verus basal groups; p < 0.05 verus control rats
insulin-resistant state. The insulin-signalling pathway on
day 15 of GI, assessed by determination of the activities
of PDK1, PKCζ , and PKB as well as translocation of
GLUT4 to the PM, was decreased compared with those
seen on day 5. A particularly notable aspect of the
present studies was the translocation of PKCζ from
the cytosol to PMs on day 15. With this move, the
association of PKCζ with PKB is increased, accompanied
by reduced reactions between PDK1 and PKB in the
membrane and inhibition of PKB activity. Our results
suggest that PKB activity was impaired by PKCζ in PM
(Figure 6). The combination of PKCζ as well as PDK1
with PKB in PM demonstrates competitive inhibition.
Therefore, we can not exclude the possibility that the
inhibition of PKB activity is partly due to the decrease
in reactions between PDK1 and PKB in the PM. In
addition, the activity of PKCζ per se was compromised
because of the increased association between PKCζ and
PKB. Whether PKCζ is directly inhibited by PKB at the
PM remains to be determined. The reduced activity of
PKCζ and PKB leads to markedly blunted translocation
of GLUT4 from low-density microsome to PM fractions
in the skeletal muscle and eventual hyperglycaemia in
rats with overt type 2 diabetes. Thus, it seems logical
to assume that, when translocating to the PM, PKCζ
seems to serve primarily as a negative feedback inhibitor
of glucose transport and maintain intracellular glucose
homeostasis under normal physiological conditions.
However, once the translocation is excessively activated,
hyperglycaemia and overt diabetes will emerge. Thus,
the long-term consequence of changed PDK1 and PKCζ
activity/localization should be considered in the context
of diabetes mellitus.
In summary, we provide evidence that translocation
of PKCζ in skeletal muscle may play a vital role in the
development of type 2 diabetes.
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